Proactive Investors
19 Aug 2026, 12:11 UTC · 2w ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
4 claims · each scored for market impact
Moderna and Merck & Co. reported that their personalized mRNA cancer vaccine, intismeran, combined with Keytruda, met its primary endpoint in a Phase 3 trial for melanoma. — A positive Phase 3 result for a first-of-its-kind personalized cancer vaccine is a major clinical breakthrough with significant valuation implications for the companies involved.
+0.80The US Treasury announced it would at least double its liquidity-support buybacks of longer-dated nominal coupon securities. — Direct government intervention to lower long-term yields reduces borrowing costs and eases systemic pressure on equity valuations.
+0.60President Donald Trump paused 50% tariffs on Canadian goods for three days due to progress toward a potential deal. — A temporary reprieve in trade tensions reduces immediate geopolitical risk for companies with cross-border Canadian trade exposure.
+0.40Continue reading
6 related stories
Top 1 mover · tap to explore
Target raised its annual sales outlook, while Lowe's forecast flat comparable sales for the year. — Mixed retail signals indicate divergent consumer spending patterns between general merchandise and discretionary home improvement.
+0.20Which stocks this story touches
Shares surged significantly following positive Phase 3 trial results for a personalized mRNA cancer vaccine.
Shares gained over 10% after positive interim results for a cancer vaccine combined with Keytruda.
Shares came under pressure due to a forecast of flat comparable sales.
Stock edged higher after the company raised its annual sales outlook.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Bloomberg Markets and Finance
1h ago
